Search

Madrigal Pharmaceuticals Inc

Suletud

SektorTervishoid

531.75 -0.16

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

530.26

Max

534.96

Põhinäitajad

By Trading Economics

Sissetulek

36M

-58M

Müük

53M

364M

Aktsiakasum

-1.99

Kasumimarginaal

-15.906

Töötajad

915

EBITDA

30M

-56M

Dividendid

By Acuity

Järgmine tulemuste avaldamine

3. nov 2026

Turustatistika

By TradingEconomics

Turukapital

-208M

13B

Eelmine avamishind

531.91

Eelmine sulgemishind

531.75

Uudiste sentiment

By Acuity

65%

35%

288 / 339 Pingereas Healthcare

Madrigal Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. sept 2026, 20:03 UTC

Social Media

Madrigal Pharmaceuticals shares are lower as CEO highlights MASH sector potential at the Cantor Fitzgerald conference amid broader market volatility and ECB rate hike effects.

3. sept 2026, 19:36 UTC

Social Media

Madrigal Pharmaceuticals is presenting five abstracts on MASH at the Paris conference on September 10, as shares trade lower today.

2. sept 2026, 21:01 UTC

Madrigal Pharmaceuticals is trading lower in after-market hours amid broader market weakness and unusual inactivity, though it remains above its 20-day moving average.

1. sept 2026, 19:36 UTC

Madrigal Pharmaceuticals shares are declining amid rising oil prices and inflation concerns. The stock initially reached a session high earlier in the session.

31. aug 2026, 21:01 UTC

Madrigal Pharmaceuticals shares are lower in after-market trading, fluctuating within a narrow range amid broader market sentiment influenced by Fed Chair Kevin Warsh's remarks.

28. aug 2026, 19:56 UTC

Madrigal Pharmaceuticals Inc shares are lower today, with no specific news identified. Broader market sentiment may be affected by inflation concerns from a Federal Reserve official.

27. aug 2026, 21:01 UTC

Madrigal Pharmaceuticals Inc shares are higher in after-market trading, continuing a cumulative gain since Thursday's close, with no specific news identified.

26. aug 2026, 22:01 UTC

Madrigal Pharmaceuticals shares are higher in after-market trading, reaching a peak of 1.05% above Wednesday's close, with no specific news identified.

21. aug 2026, 19:46 UTC

Madrigal Pharmaceuticals is lower in Friday's session, retracing from an earlier peak amid broader market pressures from rising Treasury yields and inflation concerns.

20. aug 2026, 23:46 UTC

Madrigal Pharmaceuticals shares are lower in after-market trading. Broader market declines are attributed to rising crude oil prices and geopolitical tensions.

18. aug 2026, 19:56 UTC

Madrigal Pharmaceuticals shares are lower today amid rising Treasury yields, which may be influencing investor sentiment. Earlier, the stock pulled back from a session high.

17. aug 2026, 19:35 UTC

Madrigal Pharmaceuticals is trading higher today, continuing gains since Friday's close, despite no specific company news driving the upward movement.

14. aug 2026, 19:26 UTC

Social Media

Madrigal Pharmaceuticals launches a Phase 2a study for resmetirom. Shares are lower today, pulled back from earlier gains amid broader market concerns over retail sales.

13. aug 2026, 21:01 UTC

Madrigal Pharmaceuticals Inc shares are higher in after-market trading, showing notable movement since Thursday's close, though no specific news explains the price action.

12. aug 2026, 21:01 UTC

Madrigal Pharmaceuticals shares are higher in after-market trading. Positive market sentiment follows comments on CPI reports that may impact Federal Reserve interest rate decisions.

10. aug 2026, 19:16 UTC

Madrigal Pharmaceuticals Inc shares are higher, despite no specific news. Broader market conditions reflect a decline in U.S. stock futures amid job data.

7. aug 2026, 20:02 UTC

Madrigal Pharmaceuticals shares are lower during Friday's session, continuing a decline since Thursday. The stock remains below its 20-day moving average.

6. aug 2026, 21:01 UTC

News

Madrigal Pharmaceuticals granted equity inducement awards to ten new employees, boosting shares modestly higher in after-market trading.

4. aug 2026, 20:04 UTC

Social Media
News

Madrigal Pharmaceuticals upgraded to Outperform by Wolfe Research, with a price target of $605. Shares are higher since Monday, despite a pullback earlier today.

3. aug 2026, 19:31 UTC

News
Social Media

Madrigal Pharmaceuticals shares are higher as CEO Bill Sibold notes market hesitance toward IVA due to weight gain concerns. The broader market also advances.

31. juuli 2026, 23:06 UTC

Madrigal Pharmaceuticals Inc shares are lower in after-market hours with no specific news identified. The stock remains near the lower end of its one-month range.

30. juuli 2026, 19:27 UTC

News

Madrigal Pharmaceuticals shares are lower following a widened second-quarter net loss of $57.9 million and increased operating expenses of $420.6 million.

29. juuli 2026, 22:26 UTC

Madrigal Pharmaceuticals shares are lower in after-market hours, reflecting broader market volatility following the Federal Reserve's interest rate decision and inflation concerns.

28. juuli 2026, 18:46 UTC

Madrigal Pharmaceuticals is lower today, continuing a broader decline since Monday's close. No specific news has been identified to explain the movement.

27. juuli 2026, 23:56 UTC

Madrigal Pharmaceuticals Inc is trading higher in after-market hours, reflecting a notable increase since Monday's close, despite no specific news identified.

20. juuli 2026, 16:02 UTC

Social Media

Madrigal Pharmaceuticals is lower today amid aggressive call buying and heightened market volume, with broader inflation concerns influenced by geopolitical tensions.

Võrdlus sarnastega

Hinnamuutus

Madrigal Pharmaceuticals Inc Prognoos

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

13 ratings

12

Osta

1

Hoia

0

Müü

Sentiment

By Acuity

288 / 339 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
help-icon Live chat